Despite substantial progress in the management of childhood acute myeloid leukemia (AML), only about 50% of patients are cured by intensive chemotherapy. The long-term results of clinical trials may reveal principles that can guide the development of future therapy. From 1980 to 2000, 251 patients o15 years of age with newly diagnosed AML were enrolled on one of the five consecutive St Jude AML studies. The median age of the 128 boys and 123 girls was 6.2 years; 193 were white, 45 black, and 13 of other racial groups. With the exception of one protocol (AML-83), outcomes improved in general over the two decades. The estimated 5-year event-free survival (7s.e.) was 30.875.6% for AML-80; 11.174.3% for AML-83; 35.977.4% for AML-87; 43.576.2% for AML-91; and 45.0711.1% for AML-97. Resistant or relapsed AML caused the great majority of treatment failures. Increasing the intensity of chemotherapy (AML-87) did not improve outcome, partially because of toxicity, nor did prolonging postremission therapy by adding sequential myeloablative (AML-80) or nonmyeloablative (AML-83) chemotherapy cycles. We conclude that subtype-specific therapies are needed to replace the 'one size fits all' strategy of the past two decades.
Introduction
The first large, randomized pediatric AML study at St Jude opened in 1968. Of the 58 patients treated for AML at St Jude before that time, only one survived for more than 5 years. 1 By 1973, 86 patients with newly diagnosed AML had been treated on three successive St Jude trials. With these simple antimetabolite-based regimens, the rate of complete remission (CR) was 66% and the median duration of remission was 6 months. The start of the modern era in the late 1970s saw the introduction of more intensive regimens and improved supportive care, 2 but cure rates remain low. In search of principles that can guide the design of future therapy, we analyzed the long-term results of the five most recent St Jude AML therapy trials.
Patients and methods

Patients
From 1980 to 2000, 251 patients o15 years of age with newly diagnosed AML were enrolled on one of the five consecutive St Jude AML studies (Supplementary Table 1 ). The median age was 6.2 years (range, 0.01-15.0 years). The racial makeup was 193 white, 45 black, and 13 other groups; there were 128 boys. Patients with promyelocytic leukemia were excluded from the two most recent protocols. Patients with secondary leukemia or myelodysplastic syndrome were excluded from this analysis. Patients with Down's syndrome were excluded from analysis of the AML-83, AML-87, and AML-97 protocols.
Diagnosis
The diagnosis of AML was based on the French-AmericanBritish (FAB) criteria. Each case was classified through studies of aspirated bone marrow by two St Jude pathologists. Megakaryoblastic leukemia was diagnosed by immunophenotypic findings or the presence of platelet-associated peroxidase. 3 Conventional cytogenetic studies were performed for all patients in the last four protocols and for some in AML-80. Molecular genetic testing during the two most recent trials included fluorescence in situ hybridization to detect chromosomal rearrangements, reverse transcriptase-PCR for chimeric transcripts encoded by specific translocations, and Southern blot analysis for genomic rearrangements.
Treatment
The treatment schemas of the protocols are outlined in Supplementary Table 1. The AML-80 protocol (enrollment, from  1980 to 1983) 4 compared allogeneic hematopoietic stem cell transplantation (HSCT) with sequential intensive chemotherapy for patients in first CR. Postremission chemotherapy consisted of four pairs of drugs administered sequentially over 12 months. Patients in the HSCT group received cyclophosphamide, 60 mg/ m 2 Â 2 doses and total body irradiation, 12-14 Gy fractionated as 2 Gy/day for 6-7 days or as 2 Gy twice daily for 3 days as conditioning regimen. Graft-versus-host disease (GVHD) prophylaxis consisted of methotrexate alone, methotrexate plus prednisone, or cyclosporine alone. CNS-directed therapy consisted of intrathecal methotrexate (IT MTX, 12 mg/m 2 ). Cranial radiation and five additional doses of IT MTX were administered to patients with CNS disease at diagnosis who remained disease free at the end of 12 months. The AML-83 study (1983) (1984) (1985) (1986) (1987) 5 was based on a theory that maximal early eradication of leukemia cells by using multiple noncross resistant chemotherapy agents should improve outcome. Therefore, the intensive induction regimen consisted of three sets of drugs administered in sequence (Supplementary Table 1 ). Patients with 5% or more blast cells received the subsequent course of chemotherapy immediately. Patients in CR after receiving the third combination received 16 cycles of postremission chemotherapy, each comprising seven drugs administered in sequence. HSCT was not offered to patients in first CR. CNS-directed therapy was identical to that used in the AML-80 study. In the AML-87 protocol 6 (1987-1991) , the dosages of etoposide and cytarabine were individualized to optimize systemic exposure. The initial dosage (500 mg/m 2 ) was adjusted on the basis of plasma drug concentration. CNS-directed therapy consisted of five courses of intrathecal therapy (methotrexate, hydrocortisone, and cytarabine (MHA)) with dosages dependent on age. 7 The AML-91 protocol 8 (from 1991 to 1996) was a departure from most contemporary pediatric AML studies. All patients began therapy with 2-CDA alone; patients who had a complete or partial response after 14 days received another course of 2-CDA before proceeding to postremission chemotherapy and either autologous or allogeneic HSCT during first remission. Retroviral gene-marking was used to determine the origin of relapse after autologous transplantation. 9 Patients whose leukemia did not respond to 2-CDA received two or three courses of DAV before proceeding to transplant. The conditioning regimen consisted of cytarabine, cyclophosphamide, and fractionated total-body irradiation (TBI). GVHD prophylaxis consisted of cyclosporine with either methotrexate or pentoxifyline. Unrelated-donor grafts were T-cell depleted; these patients received antithymocyte globulin before transplantation, and cyclosporine alone for prevention of GVHD. The conditioning regimen for autologous transplantation used busulfan and cyclophosphamide. CNS-directed therapy consisted of IT MHA administered monthly. The AML-97 protocol 10 (1997-2002) , built on the AML-91 study, consisted of 2-CDA given by 2-h bolus infusion plus cytarabine administered either as a continuous infusion or a 2-h bolus infusion. Initially, all patients received postremission HSCT, as in AML-91. Patients with high-risk AML (monosomy or deletion 7, 5qÀ, trisomy 11, or 8, t(9;22), secondary AML, megakaryoblastic leukemia, or the absence of remission after first course of DAV) were candidates for allogeneic HSCT. Others were eligible for autologous HSCT; the autologous marrow would be purged by two different methods and marked with a retroviral vector. In 1998, because the retroviral marker was not available, the protocol was amended to substitute two courses of intensive chemotherapy for autologous HSCT (Supplementary Table 1 ). The conditioning regimens were identical to those used in AML-91. CNS-directed therapy consisted of IT-MHA monthly for 4 months for patients without CNS leukemia at diagnosis. In patients with asymptomatic CNS leukemia, IT-MHA was administered weekly until the CSF cleared (minimum of four), then with each cycle of systemic chemotherapy. No radiotherapy was planned for these patients.
Response criteria
In all studies, CR was defined as the total disappearance of measurable disease, restored hematopoiesis (ANC 0.3-0.5 Â 10 9 /l and platelet count 30-75 Â 10 9 /l, depending on the study), absence of identifiable leukemic cells or less than 5% undifferentiated myeloblasts in the bone marrow, and normal performance status after completion of induction chemotherapy. Relapse was defined as the presence of 5% or more leukemic cells in the bone marrow or any documented extramedullary disease. Criteria for CNS involvement differed among the studies. In the first three studies, the unequivocal detection of myeloblasts in the CSF after atraumatic lumbar puncture was considered to indicate CNS leukemia. In the latter two studies, the diagnosis of CNS leukemia required five or more cells/ml of CSF and the detection of leukemic cells after cytocentrifugation.
Statistical analysis
In this review, we first summarize the findings of the initial analyses [4] [5] [6] 8, 10 and then re-examine the outcomes of these studies. We used the Kaplan-Meier method to estimate eventfree survival (EFS) and overall survival (OS) curves, and Peto and Pike's method was used to estimate the standard errors (s.e.) of these survival estimates. The benefit of transplantation was assessed by incorporating transplant status as a time-dependent covariate in a Cox proportional hazards regression analysis to account for time-to-transplant. Confidence intervals for survival estimates were based on the log-hazard. Survival is reported as the estimated probability of survival (%)7s.e. All of these methods have been described elsewhere. 11 Table 2 lists these patients' clinical and laboratory features.
Results
Supplementary
The initial report of the AML-80 4 study analyzed 87 patients. The overall remission rate was 75%. We examined recent data from 65 patients who were less than 15 years of age at enrollment. The median age at diagnosis was 7.42 years. The median white blood cell (WBC) count was 25.9 Â 10 9 /l and platelet count, 68.5 Â 10 9 /l. The absence of AML FAB groups M6 and M7 in AML-80 reflects the lack of knowledge of these subtypes at the time. As of July 2003, the 15-year EFS of the 65 patients was 29.275.5%. The 15-year EFS was 44.4714.8% for the nine patients who underwent HSCT compared with 26.875.7% for 56 patients treated with chemotherapy alone. However, after adjusting for time to transplant, we observed no significant difference in OS (P ¼ 0.52) or EFS (P ¼ 0.76) survival between these groups. Long-term disabilities in the survivors include hepatitis C (n ¼ 3) and congestive heart failure (n ¼ 2 who received chemotherapy alone). After HSCT, two patients developed osteochondroma, one, meningioma, two, multiple endocrine deficiencies, and one, avascular necrosis of the hips.
The initial analysis of the AML-83 study 5 included 68 patients. The overall remission rate was 85%. Remarkably, only one (1.5%) patient died of infectious complications during remission induction therapy. We re-examined the outcomes of 45 patients less than 15 years old at enrollment (Supplementary Table 2 ). The median age was 4.39 years. The median WBC and platelet counts were 31.0 Â 10 9 /l and 48.0 Â 10 9 /l, respectively. In all, 16 patients (36%) had a WBC count 450 Â 10 9 /l. The 5-year EFS and survival estimates were 11.074.3 and 17.875.4%, respectively. As of July 2003, the 15-year EFS estimate of these patients was only 8.973.8%. Long-term sequelae included meningioma, parotid gland carcinoma, and hepatitis C (n ¼ 1 each).
The initial analysis of the AML-87 study 6 examined 58 patients. About 50% of patients entered CR with the first course of cytarabine/etoposide. The overall rate of CR after the fourth cycle was 76%. About 3.5% of patients died from complications of early therapy. The death rate during remission in the postremission therapy phase was relatively high, about 10%. Long-term survivors have experienced several chronic medical problems. We re-examined data from 39 patients under age 15 at enrollment (Supplementary Table 2 ). The median age at diagnosis was 7.30 years. The median WBC and platelet counts were 17.3 Â 10 9 /l and 50.0 Â 10 9 /l, respectively. In all, 11 patients (28%) had a WBC count 450 Â 10 9 /l. The 5-year EFS and OS rates were 35.977.4 and 48.777.8%, respectively. The 10-year EFS and OS estimates were 33.377.3 and 48.777.8%, respectively.
The initial analysis of the AML-91 study considered 73 patients. 8 The overall remission rate was 78%. We examined recent data from 62 patients under age 15 years at enrollment on AML-91 (Supplementary Table 2 ). The median age was 4.5 years. The median WBC and platelet counts were 16.5 Â 10 9 /l and 72.0 Â 10 9 /l, respectively. In all, 17 patients (27%) had a WBC count 450 Â 10 9 /l. The EFS and OS estimates were 43.576.3 and 56.576.3% at 5 years and 41.8710.6 and 53.077.0% at 10 years. After adjustment for time-to-transplant, patients receiving chemotherapy alone were not at significantly greater risk of an adverse event than patients receiving autologous transplants (P ¼ 0.43) or allogeneic transplants (P ¼ 0.39).
The final results of the AML-97 protocol have not yet been analyzed. For the current report, we analyzed data from the first 40 patients with primary AML who were younger than 15 years at enrollment (Supplementary Table 2 ). The median age was 8.75 years. The median WBC and platelet counts were 12.4 Â 10 9 /l and 67.5 Â 10 9 /l. Eight patients (20%) had a WBC count 450 Â 10 9 /l. An interim analysis 10 showed an excellent overall response to induction therapy (CR rate 490%). The study was designed to compare the early cytoreduction and remission rate obtained with two schedules of cytarabine. In the interim analysis, the remission rate was significantly higher with a continuous infusion (63%) than with a bolus infusion (32%) of cytarabine (P ¼ 0.047); after chemotherapy with daunorubicin, cytarabine, and etoposide, the remission rates in the two groups were 96 and 91%, respectively.
As of July 2003, the 3-year EFS and survival estimates of 40 patients less than age 15 at diagnosis were 47.577.7 and 52.577.7%, respectively.
A review of presenting features and outcome
As the results of treatment differed substantially, we analyzed the estimated probability of 5-year EFS, which is a good measure of the success of treatment of AML, according to selected presenting features (Supplementary Table 3 ). Only the t(9;11) subgroup consistently had a relatively good prognosis across the St Jude AML studies. No other presenting feature appeared to be consistently associated with outcome. The overall outcome of children o15 years of age treated on the St AML studies is shown in Table 1 and Figure 1 .
Discussion
The likelihood of survival of children with AML has reached a plateau in recent years, despite the increasing intensity of treatment. 12, 13 Resistant disease remains the primary cause of treatment failure. Rates of remission as high as 90% have been achieved, but approximately 50% of those patients later succumb to the disease or the consequences of treatment. [14] [15] [16] [17] Many survivors have been exposed to large doses of anthracyclines, alkylating agents, blood products, antibiotics, and radiation therapy, all of which can cause serious long-term effects. However, the long-term consequences of treatment are comparatively poorly characterized. 18, 19 AML-83 had the poorest results of the St Jude AML trials ( Figure 1 ). Several observations may account for this outcome. The first course of induction with etoposide plus cytarabine yielded a CR rate of only 26.4%. The remission rate increased to 85% after subsequent courses that included daunorubicin, cytarabine plus thioguanine, and etoposide plus azacitidine. However, the dismal long-term survival reflects the nonmyeloablative nature of postconsolidation therapy in AML-83. The greater frequency of CNS relapse in AML-83 than in AML-80 and AML-87 is also noteworthy; the latter two trials used CNSdirected therapy like that of AML-83 but much more intense postremission therapy. Repeated courses of intensive chemotherapy that included cytarabine early in the postremission phase may have helped to prevent CNS relapse. 20 Finally, the remission induction rate after etoposide plus cytarabine was almost twice as high in the morphologic FAB M4 or M5 subtypes Table 1 Outcome of treatment of children less than age 15 years at enrollment on St Jude AML trials as that in other FAB subtypes. This observation is consistent with the greater sensitivity of M4 and M5 leukemia cells to etoposide in vitro. 5 Further, aggregate data from AML-80 and AML-83 showed that the 2-year EFS estimate of patients with M5 AML and the t(9;11) was 75%. 21 The prognostic implication of the t(9;11) was subsequently corroborated by our studies 22 and others. 23, 24 In the AML-87 protocol, one of the most intensive St Jude AML regimens to date, the dosages of both cytarabine and etoposide were adjusted to achieve a targeted plasma concentration. As expected, the combination delivered on this schedule caused severe gastrointestinal toxicity, which usually delayed the next course of chemotherapy. Despite the intensity of treatment (a 15% death rate during remission from infectious complications) and the use of HSCT for selected patients in second remission, the 10-year survival rate was only 40%. Most of the failures were bone marrow relapses; CNS relapse was not observed. The AML-87 results suggest that intensification of therapy beyond a certain threshold does not improve the outcome of AML, and undue toxicity can even decrease OS.
The AML-91 used single-agent 2-CDA to induce remission. The remission rate of 78% was comparable to those of previous St Jude AML trials. As in AML-83, patients with M5 AML, the t(9;11), or both had very good responses to 2-CDA. However, patients with M7 AML had very poor responses (no complete response among 10 patients). The use of postinduction HSCT did not improve survival in the AML-91 trial. This finding is not surprising, considering that the type of transplant -allogeneic vs autologous -was based on the availability of a matched donor. It is now known that allogeneic HSCT does not improve the survival of patients with favorable risk factors, although it may do so for patients with high-risk AML. 25, 26 The data from AML-97 are still being analyzed. This study combined cytarabine with 2-CDA in the first induction cycle. Postremission chemotherapy consisted of DAV and high-dose cytarabine. Allogeneic HSCT was recommended for patients with high-risk leukemia. More than 90% of patients with de novo AML achieved CR. Remarkably, the cumulative dose of anthracyclines in remission induction therapy was relatively low. The role of anthracycline dose intensity has not been prospectively studied in pediatric AML. In the AML-97 trial, the rate of CR was above 90% with a modest cumulative dosage of daunorubicin (90-180 mg/m 2 ) (Supplementary Table 4 ). Despite the excellent remission rate of the AML-97 protocol, preliminary analysis revealed an EFS of approximately 50% (unpublished observation). In that protocol, we began to systematically assess the significance of minimal residual disease. As recently reported, 27 this analysis revealed that a level of residual leukemia X0.1% at the end of induction therapy is an independent predictor of treatment failure. However, contrary to findings in acute lymphoblastic leukemia, the absence of residual disease at this point does not virtually assure that relapse of AML will not occur.
Remarkably, the proportion of patients with AML M7 has increased substantially in the past three St Jude protocols. The frequency of AML M7 in St Jude studies has been higher than that reported in other clinical AML trials. This difference may partly reflect the lower likelihood of enrollment of these patients on AML protocols because of their complex presenting clinical features and the difficulty of obtaining bone marrow samples for diagnosis. 3 In summary, the St Jude experience suggests that improved supportive care has contributed greatly to the development of effective remission induction therapy for pediatric AML. Early intensive chemotherapy with excellent supportive care produces remission rates above 90%. However, as demonstrated by the AML-87 protocol, indiscriminate intensification of early therapy may reduce OS. Our results and those of others show that about 40% of cases of AML are highly resistant to current therapy and that further intensification of therapy is unlikely to improve outcome. CNS-directed therapy has also been a point of contention among study groups and has not been systematically studied. The St Jude experience suggests that riskdirected triple intrathecal chemotherapy in the context of intensive systemic chemotherapy is likely to be effective even for patients with CNS leukemia, and that cranial irradiation may not be necessary. 20 Future clinical trials for AML should identify specific treatment questions for specific subsets of patients. For example, studies of the efficacy of HSCT based solely on the availability of an HLA-matched donor may not be appropriate for patients with the favorable karyotypes. A more rational approach to HSCT may have to consider the AML subtype and initial response to therapy as assessed by minimal residual disease. Also, important is the identification early in treatment of patients who are unlikely to benefit from intensive chemotherapy or HSCT and who could be invited to participate in innovative trials while their clinical condition remains good. Such clinical investigations should be conducted as multiinstitutional collaborations because of the small number of patients in specific subgroups.
